Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Which drugs should health plans cover?

31.10.2005


Five principles guide decisions that improve patient safety and lower costs, say Group Health experts



With the cost of prescription drugs rising faster than any other part of health care, more insurers and health systems have begun adopting restrictive policies for coverage of newer drugs. How can consumers and health care organizations be sure that such policies don’t lean too far in either direction--either restricting necessary treatment or wasting consumers’ premiums on expensive medicines that offer no real advantage?

These issues are addressed by experts from Group Health in an article in the October 2005 issue of the Journal of General Internal Medicine. The piece presents five principles that organizations can use to protect patients when they compare the benefits, risks, and costs of drugs to include in their "formularies," the lists of drugs approved for coverage.


"Manufacturers of new drugs make a range of claims about clinical benefits, differences in cost, and cost effectiveness," said Greg Simon, MD, MPH, a Group Health psychiatrist and researcher who is the lead author of the article. "Decision makers need some principles for sorting through those claims." While other groups have established broad principles for addressing the problem, the Group Health authors offer "more specific rules for identifying the right questions and the most important evidence," Simon explained.

In addition to Simon, co-authors on this paper include Bruce Psaty, MD, PhD, a Center for Health Studies senior investigator and University of Washington professor of medicine and epidemiology who is also a member of Institute of Medicine Committee on the Assessment of the U.S. Drug Safety System; Group Health physician Marc Mora, MD, former chair of the committee that establishes formulary policies for Group Health; and Group Health pharmacist Jennifer Berg Hrachovec, PharmD, MPH.

The five principles, described in more detail below, are:

1. Give more weight to true experiments than to models or simulations, and carefully examine assumptions of such models.

2. Give more weight to real health outcomes than changes in risk factors.

3. Look at the full range of alternatives rather than those selected by industry when considering claims for advantages of new treatments.

4. Understand that variation in effects across individuals or subgroups argues against restrictions on first-line treatment, but only if those differences are predictable.

5. Understand that variation in effects argues against requiring changes in ongoing treatment.

"The money we have available for health care is not unlimited," said Simon. "Health insurers and government agencies that pay for health care have a responsibility to make sure the money we have is used for the greatest benefit. Our society tends to assume that a newer, more expensive treatment must be more effective. That assumption can be bad for our pocketbooks and our health."

Principles for evidence-based drug formulary policy

1. Give more weight to true experiments than to models or simulations, and carefully examine assumptions of such models.

The highest standard for finding true differences between newer and older treatments is the "randomized controlled trial," where study participants are assigned to different treatments by chance. Those "gold standard" comparisons are costly and may take years to complete. Policy makers sometimes rely on simulated comparisons, but those comparisons are often based on expert opinion and subject to bias. "When models or simulations are the best data available, appropriate skepticism is necessary," the authors write.

As an example, they point to Cox-2 inhibitor drugs such as Vioxx and Celebrex, which are more expensive, but no more effective on average, than older anti-inflammatory drugs. Simulated comparisons supported by the pharmaceutical industry showed that Cox-2 inhibitors could save money in the long run by reducing the risk of ulcers and intestinal bleeding. But that claim was not consistently demonstrated in randomized comparisons. The most recent evidence now finds that Cox-2 inhibitors probably do not reduce intestinal side effects and probably do increase risk of heart problems.

"Fortunately, many health care organizations had weighed the true scientific evidence of the potential risks and benefits of these drugs and decided years ago not to include them in their formularies," said Mora. "The principles we present can help organizations make these kinds of sound decisions in the interest of patient safety."

2. Give more weight to real health outcomes than changes in risk factors.

Comparisons should give more credit to medications that are actually proven to result in less illness and fewer deaths, rather than simply changing risk factors. For example, many long-term medications, such as cholesterol or blood pressure drugs, are prescribed to reduce future risk of disease. While newer blood pressure drugs have been shown to reduce blood pressure, older and more affordable drugs are probably more effective for actually preventing heart disease, explained Simon.

3. Look at the full range of alternatives rather than those selected by industry when considering claims for advantages of new treatments.

Studies needed for new drug approval often compare a placebo with a current standard treatment. But sometimes there are many standard treatments available, and the manufacturer of a new drug may not always choose the most informative comparison. Psaty and his colleagues have developed a method called "network meta-analysis" that can be used to make valid comparisons across several treatments that are studied separately. This can be "especially important when the comparisons most interesting to clinicians and policy-makers differ from those that are most interesting or advantageous to research sponsors," the authors write.

4. Understand that variation in effects across individuals or subgroups argues against restrictions on first-line treatment, but only if those differences are predictable.

Drugs approved for the same problem often show equal efficacy on average, but their effects can vary widely between individuals, the authors explain. "This …can be misinterpreted to support either unnecessarily broad or inappropriately restrictive formulary policies." If it’s not possible to predict at the beginning of treatment which drug will have the best effect, then starting with the most affordable alternative makes sense, the authors contend. But a more expensive medication is often justified for patients who respond poorly to first-line treatment.

The authors use the class of drugs for depression known as serotonin reuptake inhibitors (SRIs) as an example. Direct randomized comparisons of SRIs show no difference in average effectiveness. But studies also show that half the patients who fail to respond to one SRI may do well on another. It’s not possible to predict who will do well on which drug at the beginning of treatment. Therefore, it makes sense for an insurance company to only cover the most affordable drug for anyone starting treatment for the first time, the authors write. Patients who do poorly with the first medication should be allowed to use one of the more expensive alternatives.

5. Understand that variation in effects argues against requiring changes in ongoing treatment.

With this principle, the authors argue that formulary changes should not necessarily result in requirements that patients switch to new drugs. "In addition to concern about variability in effect, decisions …must consider added visits and other costs of medication changes, as well as the likelihood that many physicians and patients may be hesitant to disrupt stable treatment," the authors write.

About Group Health and the Center for Health Studies

Group Health is a consumer-governed, nonprofit health care system that coordinates care and coverage. Based in Seattle, Group Health and Group Health Options, Inc. serve nearly 550,000 members in Washington and Idaho. Group Health’s Center for Health Studies conducts research related to prevention, diagnosis, and treatment of major health problems. The Center for Health Studies is funded primarily through government and private research grants.

Joan DeClaire | EurekAlert!
Further information:
http://www.ghc.org

More articles from Health and Medicine:

nachricht The genes are not to blame
20.07.2018 | Technische Universität München

nachricht Targeting headaches and tumors with nano-submarines
20.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>